LATS1 and glioma: Previous studies have shown that the expression of LATS1 is downregulated in malignant mesothelioma [33], glioma [34], NSCLC [35] and ovarian tumors [36] and represents an independent prognostic indicator for the survival and prognosis of patients with glioma and ovarian cancer [34–36].